Last reviewed · How we verify
Placbo
Placbo is a Small molecule drug developed by Hans-Peter Landolt. It is currently in Phase 1 development.
Placbo is a treatment that has been studied in various conditions, including Circadian Rhythm Sleep Disorder, Jet Lag Type, and Plantar Warts, as part of interventions involving Bright Light, Bright Light + Exercise + Melatonin, and Control.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placbo |
|---|---|
| Sponsor | Hans-Peter Landolt |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers (NA)
- A Study of SRSD216 in Patients With Elevated Lipoprotein (a) (PHASE1, PHASE2)
- The Role of the LC-NA System in Experimental Sleep Fragmentation (PHASE1)
- Effects of Compound Probiotics-Polygonatum Sibiricum on Liver Health and Metabolism in Middle-aged and Elderly People (NA)
- KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy (PHASE2, PHASE3)
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (PHASE3)
- Facilitating Adjustment to Simulated Jet Lag (NA)
- Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placbo CI brief — competitive landscape report
- Placbo updates RSS · CI watch RSS
- Hans-Peter Landolt portfolio CI
Frequently asked questions about Placbo
What is Placbo?
Who makes Placbo?
What development phase is Placbo in?
Related
- Manufacturer: Hans-Peter Landolt — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing